PHME Stock Overview

A biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. More details

PHME fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	6/6
Past Performance	4/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 45.5% below our estimate of its fair value

Earnings are forecast to grow 40.82% per year

Earnings grew by 2197.7% over the past year

Risk Analysis

High level of non-cash earnings

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Pharma Mar, S.A. Competitors

Bioventix

AIM:BVXP

UK£138.3m

HUTCHMED (China)

AIM:HCM

UK£1.9b

China Resources Boya Bio-pharmaceutical GroupLtd

SZSE:300294

CN¥13.9b

Hikma Pharmaceuticals

LSE:HIK

UK£4.5b

Price History & Performance

Summary of share price highs, lows and changes for Pharma Mar
Historical stock prices
Current Share Price	€87.75
52 Week High	€95.95
52 Week Low	€47.49
Beta	-0.050
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	36.00%
5 Year Change	n/a
Change since IPO	-23.89%

Recent updates

Shareholder Returns

	PHME	GB Biotechs	GB Market
7D	-8.5%	-1.4%	-0.3%
1Y	n/a	-11.1%	6.5%

Return vs Industry: Insufficient data to determine how PHME performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how PHME performed against the UK Market.

Price Volatility

Is PHME's price volatile compared to industry and market?
PHME volatility
PHME Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.9%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	9.9%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: PHME's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine PHME's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1986	500	Jose Fernandez Sousa-Faro	www.pharmamar.com

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer.

Pharma Mar, S.A. Fundamentals Summary

How do Pharma Mar's earnings and revenue compare to its market cap?
PHME fundamental statistics
Market cap	€1.56b
Earnings (TTM)	€26.13m
Revenue (TTM)	€174.86m

59.6x

P/E Ratio

8.9x

P/S Ratio

Is PHME overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHME income statement (TTM)
Revenue	€174.86m
Cost of Revenue	€8.18m
Gross Profit	€166.67m
Other Expenses	€140.55m
Earnings	€26.13m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	1.49
Gross Margin	95.32%
Net Profit Margin	14.94%
Debt/Equity Ratio	23.0%

How did PHME perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

-647%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/23 07:24
End of Day Share Price	2025/03/17 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharma Mar, S.A. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Guilherme Sampaio	Banco BPI, S.A.
Patricia Cifuentes	Bestinver Sociedad De Valores, S.A
Keay Nakae	Chardan Capital Markets, LLC